U.S. panel rejects anticlotting drug from AstraZeneca
A U.S. Food and Drug Administration panel of experts declined to recommend approval of AstraZeneca PLC's anticlotting durg Exanta. The panel said the benefits of Exanta didn't outweigh the risk of